Causal Network Modeling Provides Powerful Approach to Modeling Complex
Biological Systems for Type 2 Diabetes
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration with Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, has won Bio-IT World magazine's 2008 Best Practices Award in the Drug Discovery & Development category. The project was focused on discovering mechanisms of action (MOA) for Type 2 diabetes.
The two companies collaborated to further characterize the molecular MOA of Sirt1 activating compounds. In blinded analysis, Genstruct's causal network modeling (CNM) approach concluded that the strongest hypothesis for the results seen in the Sirtris Type 2 diabetes study was caloric restriction (CR) -- showing that Sirtris' SIRT1 activators are mimicking the effects of CR. These results were confirmed by in vitro and in vivo experimentations.
"We are honored that our collaboration with Sirtris has been recognized for our unique approach to modeling complex biological systems," said Dr. Keith O. Elliston, president and CEO at Genstruct. "Using our CNM platform, we were able to help develop a deep understanding of the SIRT1 pathway and allowed Sirtris to efficiently analyze a vast quantity of data. Sirtris has been a valued research partner for our firm."
Genstruct's unique CNM platform for systems biology has been designed
to integrate and model data from multiple large-scale measurement
|SOURCE Genstruct Inc.|
Copyright©2008 PR Newswire.
All rights reserved